Previous 10 | Next 10 |
Halvorsen's 13F portfolio value decreased from $36.37B to $33.58B. The number of positions decreased from 96 to 94. Viking Global added Bank of America while reducing JPMorgan Chase and dropping Walt Disney. The top three positions are Microsoft, BridgeBio Pharma, and Fidelity Nat...
- 44,000 square foot facility includes fill-finish and analytical laboratory capabilities with potential for site expansion - Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has reached an agreement to purchase a drug product manufacturing facility from EirGe...
Horizon Therapeutics ([[HZNP]] -0.4%) presents new data from the ongoing PROTECT study, which provides further insight into utility of KRYSTEXXA (pegloticase injection) as a treatment for people with uncontrolled gout (chronic gout refractory to conventional therapies) who have undergone a ki...
-- Early data from ongoing PROTECT trial suggest stable and durable response to KRYSTEXXA® (pegloticase injection) therapy in treating uncontrolled gout among people with kidney transplants -- -- Data on the company’s investigational compound (HZN-4920) under evalu...
Horizon Therapeutics (HZNP) has enrolled the first patient in the ADVANCE trial evaluating the use of KRYSTEXXA (pegloticase injection) with methotrexate for certain people with uncontrolled gout.The combination treatment was tried on people who were not able to achieve a complete response wh...
-- Trial evaluates opportunity to improve outcomes based on emerging data that immunomodulation may offer clinical benefit -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in the ADVANCE trial evaluating the concomitant use of KRYSTEX...
John Paulson’s 13F portfolio value increased from $3.85B to $4.35B this quarter. Paulson & Company added Perpetua Resources and increased Alexion Pharmaceuticals while dropping Discovery and ViacomCBS during the quarter. Their top three positions are at 45% of the entir...
Horizon's Q1 2021 results were good considering Tepezza's supply disruption. Tepezza sales resumed in early Q1 and it is off to a strong start with record patient enrollment forms in April. To help Tepezza grow, Horizon has doubled its sales force and initiated disease and brand a...
Biotech M&A, which has been relatively quiet so far this year, is poised to pick up due to more reasonable prices for biotech companies, according to Jefferies analyst Michael Yee."Typically, we see 3-5 [month] corrections…[and] then pharma starts to step in and finalize deals,...
Horizon Therapeutics is a biotechnology company focused on capital efficiency and commercialization. The company has built a strong track record acquiring assets early and then efficiently bringing them to market. This has led to their business model increasingly resembling Danahe...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...